Abstract
We aimed to examine the frequency of high-dose (defined as mean chlorpromazine mg equivalent doses above 1000) antipsychotic prescriptions in schizophrenia and their clinical correlates in the context of a comparison between studies in 2001 and 2004 within six East Asian countries and territories. Prescriptions of high-dose antipsychotic for a sample of 2136 patients with schizophrenia from six countries and territories (mainland China, Hong Kong, Korea, Japan, Taiwan and Singapore) were evaluated in 2004 and compared with data obtained for 2399 patients in 2001. Overall, the comparison between 2001 and 2004 showed a significant decrease in high-dose antipsychotic use from 17.9 to 6.5% [odds ratio (OR) 0.32, 95% confidence interval (CI) 0.26, 0.39, P < 0.001]. Patients who received high-dose antipsychotics were significantly more likely to have multiple admissions (OR 1.96, 95% CI 1.16, 3.33, P = 0.009), more positive psychotic symptoms such as delusions (OR 2.05, 95% CI 1.38, 3.05, P < 0.001) and hallucinations (OR 1.85, 95% CI 1.30, 2.64, P = 0.001), but less likely to have negative symptoms (OR 0.58, 95% CI 0.40, 0.82, P = 0.002). Multivariate regression analyses revealed that prescription of high-dose antipsychotics was als...Continue Reading
References
Dec 1, 1976·Archives of General Psychiatry·H A McClellandA A Schiff
Jul 1, 1992·Archives of General Psychiatry·L FardeG Sedvall
Aug 1, 1991·Archives of General Psychiatry·J P McEvoyS Steingard
Jan 1, 1988·Archives of General Psychiatry·R J BaldessariniM H Teicher
Jun 1, 1987·The American Journal of Psychiatry·J M ZitoC Siegel
Feb 15, 1993·Biological Psychiatry·A L NordströmG Uppfeldt
Dec 31, 1997·BMJ : British Medical Journal·J A Knottnerus, G J Dinant
Feb 7, 1998·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J M KaneN R Schooler
Mar 21, 1998·Schizophrenia Bulletin·A F Lehman, D M Steinwachs
Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Jan 19, 2000·European Journal of Clinical Pharmacology·G Tognoni
Mar 30, 2000·The American Journal of Psychiatry·S KapurS Houle
Apr 12, 2000·International Clinical Psychopharmacology·M KrauszD Naber
Apr 19, 2000·Journal of Clinical Psychopharmacology·J VolavkaN Bark
Jun 10, 2000·The Journal of Clinical Psychiatry·J T WalkupS Hansell
Sep 5, 2001·Psychiatric Services : a Journal of the American Psychiatric Association·M ValensteinS Visnic
Mar 2, 2002·Applied Occupational and Environmental Hygiene
Jun 6, 2002·Schizophrenia Bulletin·Nancy H CovellSusan M Essock
Oct 24, 2002·British Journal of Clinical Pharmacology·Gabor S UngvariHelen F K Chiu
Nov 26, 2002·The Journal of Clinical Psychiatry·Francisco J Diaz, Jose De Leon
Jun 26, 2003·The Journal of Clinical Psychiatry·Scott W Woods
Sep 5, 2003·Psychiatric Services : a Journal of the American Psychiatric Association·Nancy L SohlerMark Olfson
Oct 23, 2003·International Clinical Psychopharmacology·Takefumi SuzukiHaruo Kashima
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
Jun 29, 2004·Clinical Therapeutics·Remo SusannaUNKNOWN Latin American Glaucoma Society
Jul 17, 2004·British Journal of Clinical Pharmacology·Kang SimChay H Tan
Aug 25, 2004·The Journal of Clinical Psychiatry·Sheila BottsJose de Leon
Oct 7, 2004·Pharmacopsychiatry·K SimC H Tan
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanUNKNOWN Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jan 13, 2006·The Journal of Clinical Psychiatry·Christoph U Correll
Jan 21, 2006·Acta Psychiatrica Scandinavica·R M CarnahanE A Chrischilles
Oct 3, 2006·International Clinical Psychopharmacology·Corrado BarbuiMichele Tansella
May 24, 2007·International Clinical Psychopharmacology·Corrado BarbuiLuigi Grassi
Citations
Oct 16, 2014·Indian Journal of Psychiatry·Sandeep GroverKamla Deka
Aug 10, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Dimitrios KontisEleftheria Tsaltas
Jun 2, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Meng-Ting WangAgnes L F Chan
Jul 14, 2011·Human Psychopharmacology·Yu-Tao XiangNaotaka Shinfuku
Sep 10, 2014·Pharmacoepidemiology and Drug Safety·Chieko IshiguroSusan Jick
Aug 14, 2013·International Journal of Geriatric Psychiatry·Yu-Tao XiangNaotaka Shinfuku
Jun 6, 2013·ISRN Psychiatry·Aulikki Ahlgrén-RimpiläinenIlpo Rimpiläinen
Jun 30, 2012·Schizophrenia Research·Daimei SasayamaHiroshi Kunugi
Feb 5, 2011·Journal of Psychopharmacology·Thomas R E Barnes, UNKNOWN Schizophrenia Consensus Group of British Association for Psychopharmacology
Apr 27, 2012·The Australian and New Zealand Journal of Psychiatry·Elise V GriffithsM Joy Spark
Dec 15, 2010·The Australian and New Zealand Journal of Psychiatry·Yu-Tao XiangNorman Sartorius
May 15, 2013·The Australian and New Zealand Journal of Psychiatry·Daeyoung RohYoung-Chul Jung
Sep 8, 2009·Current Opinion in Psychiatry·Hiroto Ito
Apr 11, 2014·Journal of Clinical Psychopharmacology·Natasa GisevTimothy F Chen
Apr 24, 2013·Journal of Clinical Psychopharmacology·Bo-Jian WuShin-Min Lee
May 21, 2020·The Psychiatric Quarterly·Sérgio MartinhoCláudio Laureano
Aug 14, 2019·Early Intervention in Psychiatry·Lida-Alkisti XenakiNikos C Stefanis
Mar 2, 2018·Journal of Psychopharmacology·Yanling ZhouYuping Ning
May 31, 2014·Journal of Clinical Psychopharmacology·Heidi TaipaleSirpa Hartikainen
May 27, 2020·Neuropsychopharmacology Reports·Tatsuichiro TakahashiYuichi Imanaka